This study aims to evaluate real-world triptan treatment patterns.

 This retrospective cohort study utilizing deidentified data from the second-largest healthcare provider in Israel. Eligible patients were members aged 21 years or older who had an index-date (first prescription/ dispensation) between 2012 and 2022 and were followed until end of 2023. Triptan discontinuation was defined as the absence of additional dispensations between last dispensation date (plus 90 days) and the end of follow-up period, except where treatment cessation was due to contraindications. Time to discontinuation was analyzed using Kaplan-Meier curves.

This study indicates a low treatment rate (assuming 10% migraine prevalence rate) and among the treated population, a high discontinuation rate. This may suggest potentially suboptimal response or tolerability issues with current standard of care. Additional research is needed to understand these phenomena and to identify risk markers for treatment failure which may enable physicians to recommend acute therapies more effectively.